checkAd

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.

The following posters will be presented:

IPH5201 as monotherapy or in combination with durvalumab in advanced solid tumors (AstraZeneca)

  • Abstract Number: 472
  • Session Name: Poster Display 188P
  • Session Time: 8 December, 12:30-13:15
  • Location: Palexpo exhibition centre – Foyer ABC
  • Presenter: Dr. Martina Imbimbo, Head of Clinic for the Immuno-oncology Department within the Department of Oncology at UNIL CHUV (Lausanne, Switzerland)

Combination of IPH5201, a block antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale

  • Abstract Number: 384
  • Session Name: Poster Display 190P
  • Session Time: 8 December, 12:30-13:15
  • Location: Palexpo exhibition centre – Foyer ABC
  • Presenter: Carine Paturel, Senior Director, Research and Drug Development, Products Portfolio Strategy, Innate Pharma (Marseille, France)

A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES) (Institut Paoli-Calmettes)

  • Abstract Number: 290
  • Session Name: Poster Display 199TiP
  • Session Time: 8 December, 12:30-13:15
  • Location: Palexpo exhibition centre – Foyer ABC
  • Presenter: Dr. Anthony Gonçalves, Professor of Medical Oncology, Institut Paoli-Calmettes (Marseille, France)

The posters will be available on the Publications section of Innate’s website following the meeting.

About IPH5201

IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment. It is being developed in partnership with AstraZeneca.

A first-in-human, multi-centre, non-randomised, open-label, phase 1 study (NCT04261075) sponsored by AstraZeneca assessed the safety, efficacy, pharmacokinetics and pharmacodynamics of IPH5201 as monotherapy and in combination with durvalumab in patients with advanced solid tumors.

A Phase 2 clinical trial conducted by Innate in lung cancer is in planning.

About IPH5301

IPH5301 is a CD73-blocking monoclonal antibody currently in an investigator-sponsored Phase 1 trial in collaboration with the Institut Paoli-Calmettes (IPC) and Oncodistinct Network.

Seite 1 von 3


Nachrichtenquelle: Business Wire (engl.)
 |  101   |   |   

Schreibe Deinen Kommentar

Disclaimer

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022 Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O …

Nachrichten des Autors

236 Leser
180 Leser
160 Leser
156 Leser
144 Leser
1404 Leser
756 Leser
540 Leser
456 Leser
400 Leser
3232 Leser
2096 Leser
1916 Leser
1604 Leser
1404 Leser
7528 Leser
3232 Leser
3053 Leser
2934 Leser
2493 Leser